Opinion

Video

Overview of Novel Treatments for Retinal Vascular Diseases

A panelist discusses novel treatments for retinal vascular diseases, including faricimab, aflibercept, and port delivery system with ranibizumab.

Video content above is prompted by the following:
Could you briefly provide an overview of the new treatments available for retinal vascular diseases?

  1. Faricimab
  2. Aflibercept 8mg
  3. port delivery system with ranibizumab

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Tiimes) EyeCon 2025: Sruthi Arepalli, MD, spotlights a deep dive orbital tour of the eye
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Related Content
(Image credit: AdobeStock/FourLeafLover) Glaucoma-focused session with Angelo P. Tanna, MD, launches Northwestern University’s “Dinner with the Experts” series
September 12th 2025

Glaucoma-focused session with Angelo P. Tanna, MD, launches Northwestern University’s “Dinner with the Experts” series

3 Things You Should Know About the GA Pipeline
September 12th 2025

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

(Image credit: AdobeStock/racesy) Q&A: Inside the CCOI Myopia Workshop with Assoc Prof Daniel Ting
September 12th 2025

Q&A: Inside the CCOI Myopia Workshop with Assoc Prof Daniel Ting

3 Things You Should Know About the GA Pipeline
September 12th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: Ophthalmology Times) From firsts to the future: A pioneer's perspective on ophthalmology
September 12th 2025

From firsts to the future: A pioneer's perspective on ophthalmology

(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
September 12th 2025

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

© 2025 MJH Life Sciences

All rights reserved.